June 7, 2012
Dainippon Sumitomo Pharma (DSP) and Shionogi & Co. announced on June 5 that the two companies entered into a comarketing agreement for DSP-8153, a fixed-dose combination drug of the antihypertension treatments of irbesartan, an angiotensin II receptor blocker (ARB), and...read more